• Revenue growth outlook: Sun Pharma is guiding for high single-digit revenue growth in FY27 due to macroeconomic, geopolitical, and tariff uncertainties, while abstaining from providing specific margin guidance.
• Innovative medicines portfolio: The division generated $354 million in Q4 (up 20% year-on-year) and $1.4 billion in FY26, with management guiding for double-digit growth driven by products such as Ilumya, Cequa, Odomzo, and Winlevi.
• Organon acquisition financing: The transaction is expected to close by Q4 FY27 to deliver $350 million in operational synergies over 2 to 3 years, funded by $2 billion to $2.5 billion of internal cash and committed bank facilities of $12 billion.
• Halol regulatory status: All required remediation work at the Halol facility has been completed, though the company is still waiting for a confirmed inspection timeline from the US FDA.
• Domestic market performance: Sun Pharma aims to continue growing faster than the industry following 14% domestic growth in FY26, with newly launched semaglutide performing well in India and international expansion being evaluated.